Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes

Ingram, Cory; Brubaker, Richard F.

doi:10.1016/s0002-9394(99)00179-8

Cited by 65 publications

(32 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In humans, no differences were found in the IOP effects of the two CAI, whereas brinzolamide appeared to be slightly more effective in reducing aqueous humour flow than dorzolamide. 37 A comparative study between brinzolamide and dorzolamide is necessary to detect possible different effects on ocular blood flow in humans.…”

Section: Discussionmentioning

confidence: 99%

Effects of brinzolamide on ocular haemodynamics in healthy volunteers

Kaup

Plange²,

Niegel³

et al. 2004

British Journal of Ophthalmology

View full text Add to dashboard Cite

Aim: A prospective, randomised study to evaluate effects of brinzolamide on ocular haemodynamics in healthy volunteers. Methods: 30 volunteers (12 men, 18 women; 28.3 (SD 7.8) years) were prospectively randomised to either brinzolamide or placebo during a 2 week double masked treatment trial. Examinations were performed at baseline and after 2 weeks of treatment. Intraocular pressure was measured and automatic static perimetry (Humphrey field analyser, 24-2) and contrast sensitivity (CSV 1000, Vector Vision) were performed. Retrobulbar blood flow velocities (peak systolic and end diastolic velocity) and resistive indices (RI) of ophthalmic artery, central retinal artery and of temporal and nasal short posterior ciliary arteries were measured by colour Doppler imaging (Sonoline Sienna Siemens). In video fluorescein angiograms (scanning laser ophthalmoscope, Rodenstock) arteriovenous passage time (AVP, dilution curves) and peripapillary diameters of retinal arterioles and venules were measured by means of digital image analysis. Results: Intraocular pressure was significantly decreased by brinzolamide (p,0.0001). Neither brinzolamide nor placebo changed visual field global indices after treatment. Contrast sensitivity at 3 cycles per degree was significantly higher in the placebo group (p,0.05). Apart from an increase of RI in ophthalmic artery under placebo treatment (p,0.05) there was no effect in retrobulbar haemodynamics in both groups. Brinzolamide therapy alone resulted in a significant reduction of AVP compared to baseline (p,0.05), while peripapillary retinal vessels diameters remained unaffected. Conclusions: Apart from the expected decrease of intraocular pressure brinzolamide showed no significant change in retrobulbar haemodynamics, but a significant shortening of AVP. Since in glaucoma AVP is prolonged indicating vascular dysfunction this effect might be beneficial in glaucoma therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of brinzolamide on ocular haemodynamics in healthy volunteers

Kaup

Plange²,

Niegel³

et al. 2004

British Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…[4][5][6][7][8] Brinzolamide is a new carbonic anhydrase inhibitor that reduces IOP by inhibiting aqueous humor formation. [9][10][11] The IOP-lowering efficacy of brinzolamide 1% is reported to be equal to or higher than that of dorzolamide 2%, 11,12 and, as with other carbonic anhydrase inhibitors, a further IOP-lowering efficacy is expected when additionally combined with a prostaglandin analog. 13,14 In addition, although timolol with the same IOP-lowering mechanism of inhibiting aqueous humor formation does not have the IOP-lowering efficacy during the nighttime, 5,8 carbonic anhydrase inhibitors are said to have the IOP-lowering efficacy throughout the night.…”

Section: Methodsmentioning

confidence: 99%

Effect of Concomitant Use of Latanoprost and Brinzolamide on 24-hour Variation of IOP in Normal-tension Glaucoma

Nakamoto

Yasuda

2007

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

“…Ethoxzolamide (3) and dichlorophenamide (4) are two other carbonic anydrase inhibitors, formulated for topical ophthalmic use (see Figure 1 for the structures) [22,23]. Nevertheless, people taking these two drugs also experience side effects as stinging, burning, blurred vision, upset stomach, dry eye, headache or dizziness [22,[24][25][26]. The purpose of the present study was to synthesise and investigate some new inhibitors of carbonic anydrase isoenzymes with a potential use in the treatment of glaucoma.…”

Section: Introductionmentioning

confidence: 99%